Markers of immune activation and inflammation in individuals with post-acute sequelae of SARS-CoV-2 infection

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES

Antiviral Therapy Pub Date : 2021-07-11 DOI:10.1101/2021.07.09.21260287

M. Peluso, S. Lu, A. Tang, M. Durstenfeld, Hsi-en Ho, S. Goldberg, C. Forman, S. Munter, R. Hoh, V. Tai, A. Chenna, B. C. Yee, J. W. Winslow, C. Petropoulos, B. Greenhouse, P. Hunt, P. Hsue, J. N. Martin, J. D. Kelly, D. Glidden, S. Deeks, T. Henrich

{"title":"Markers of immune activation and inflammation in individuals with post-acute sequelae of SARS-CoV-2 infection","authors":"M. Peluso, S. Lu, A. Tang, M. Durstenfeld, Hsi-en Ho, S. Goldberg, C. Forman, S. Munter, R. Hoh, V. Tai, A. Chenna, B. C. Yee, J. W. Winslow, C. Petropoulos, B. Greenhouse, P. Hunt, P. Hsue, J. N. Martin, J. D. Kelly, D. Glidden, S. Deeks, T. Henrich","doi":"10.1101/2021.07.09.21260287","DOIUrl":null,"url":null,"abstract":"BACKGROUND: The biological processes associated with post-acute sequelae of SARS-CoV-2 infection (PASC) are unknown. METHODS: We measured soluble markers of inflammation in a SARS-CoV-2 recovery cohort at early (<90 days) and late (>90 days) timepoints. We defined PASC as the presence of one or more COVID-19-attributed symptoms beyond 90 days. We compared fold-changes in marker values between those with and without PASC using mixed effects models with terms for PASC and early and late recovery time periods. RESULTS: During early recovery, those who went on to develop PASC generally had higher levels of cytokine biomarkers including TNF-alpha (1.14-fold higher mean ratio, 95%CI 1.01-1.28, p=0.028) and IP-10 (1.28-fold higher mean ratio, 95%CI 1.01-1.62, p=0.038). Among those with PASC, there was a trend toward higher IL-6 levels during early recovery (1.28-fold higher mean ratio, 95%CI 0.98-1.70, p=0.07) which became more pronounced in late recovery (1.44-fold higher mean ratio, 95%CI: 1.11-1.86, p<0.001). These differences were more pronounced among those with a greater number of PASC symptoms. CONCLUSIONS: Persistent immune activation may be associated with ongoing symptoms following COVID-19. Further characterization of these processes might identify therapeutic targets for those experiencing PASC.","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2021-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1101/2021.07.09.21260287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 8

Abstract

BACKGROUND: The biological processes associated with post-acute sequelae of SARS-CoV-2 infection (PASC) are unknown. METHODS: We measured soluble markers of inflammation in a SARS-CoV-2 recovery cohort at early (<90 days) and late (>90 days) timepoints. We defined PASC as the presence of one or more COVID-19-attributed symptoms beyond 90 days. We compared fold-changes in marker values between those with and without PASC using mixed effects models with terms for PASC and early and late recovery time periods. RESULTS: During early recovery, those who went on to develop PASC generally had higher levels of cytokine biomarkers including TNF-alpha (1.14-fold higher mean ratio, 95%CI 1.01-1.28, p=0.028) and IP-10 (1.28-fold higher mean ratio, 95%CI 1.01-1.62, p=0.038). Among those with PASC, there was a trend toward higher IL-6 levels during early recovery (1.28-fold higher mean ratio, 95%CI 0.98-1.70, p=0.07) which became more pronounced in late recovery (1.44-fold higher mean ratio, 95%CI: 1.11-1.86, p<0.001). These differences were more pronounced among those with a greater number of PASC symptoms. CONCLUSIONS: Persistent immune activation may be associated with ongoing symptoms following COVID-19. Further characterization of these processes might identify therapeutic targets for those experiencing PASC.

查看原文本刊更多论文

SARS-CoV-2感染急性后后遗症患者的免疫激活和炎症标志物

背景:与SARS-CoV-2感染急性后后遗症(PASC)相关的生物学过程尚不清楚。方法:我们在SARS-CoV-2康复队列的早期(90天)时间点测量了可溶性炎症标志物。我们将PASC定义为超过90天存在一种或多种与covid -19相关的症状。我们使用带有PASC术语和早期和晚期恢复时间的混合效应模型，比较了有PASC和没有PASC的标记值的倍数变化。结果:在早期恢复期间，继续发展为PASC的患者通常具有更高水平的细胞因子生物标志物，包括tnf - α(平均比值高1.14倍，95%CI 1.01-1.28, p=0.028)和IP-10(平均比值高1.28倍，95%CI 1.01-1.62, p=0.038)。在PASC患者中，IL-6水平在恢复早期有升高的趋势(平均比值高1.28倍，95%CI: 0.98 ~ 1.70, p=0.07)，在恢复晚期更为明显(平均比值高1.44倍，95%CI: 1.11 ~ 1.86, p<0.001)。这些差异在PASC症状较多的人群中更为明显。结论:持续的免疫激活可能与COVID-19后持续的症状有关。对这些过程的进一步表征可能会确定PASC患者的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral Therapy 医学-病毒学

CiteScore

2.60

自引率

8.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.